Press Release
Lantheus Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Patients
May 13, 2022
Read More at Our Investor SiteWe do it by making a difference in the lives of our patients. Stay current with the latest news, information and events at Lantheus. Please visit our investor site for a complete list of recent and archived press releases. Follow us on LinkedIn for social media updates.
For media resources, including images, logos, videos, and more, browse our media library.
Press Release
May 13, 2022
Read More at Our Investor Site